BioPharmSignal logoBioPharmSignal

Biotech News

Biote Reports Second Quarter 2025 Financial Results

biote Corp (BTMD)biote CorpEarnings

Q2 financial performance driven by strong dietary supplement sales and gross margin expansion Launched corporate reorganization to increase new clinic and procedure growth Decisive actions position Biote for sustainable long-term growth and value creation Second Quarter 2025 Financial Highlights

Related news

BTMDbiote Corp2026-08-05 20:05 EST

Biote Reports Second Quarter 2026 Financial Results

BTMDbiote Corp2026-07-22 20:05 EST

Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call

View all latest news

biote Corp

Hormone Optimization Biote operates a practitioner-led platform focused on hormone optimization and healthy aging. Its principal offering uses bioidentical hormone pellets implanted during office-based procedures. Practitioner Network The company trains and certifies medical practitioners, supplies procedure products and supports clinics...

Recent company news

BTMDbiote Corp2026-08-05 20:05 EST

Biote Reports Second Quarter 2026 Financial Results

BTMDbiote Corp2026-07-22 20:05 EST

Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call

BTMDbiote Corp2026-06-01 12:00 EST

Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer

BTMDbiote Corp2026-05-28 13:00 EST

Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO

BTMDbiote Corp2026-05-06 20:05 EST

Biote Reports First Quarter 2026 Financial Results

Stock data

Close
1.63 USD
Market cap
65.21M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States